Filtered By:
Drug: Aleve

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 42 results found since Jan 2013.

FDA strengthens warning that NSAIDs increase heart attack and stroke risk
Back in 2005, the FDA warned that taking nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen increased the risk of having a heart attack or stroke. Last week it took the unusual step of further strengthening this warning. This was done on the advice of an expert panel that reviewed new information about NSAIDs and their risks. Because NSAIDs are widely used, it’s important to be aware of downsides of taking an NSAID and to take steps to limit the risk. Many people take NSAIDs to relieve mild to moderate pain. These medications may be particularly effective in conditions in which pain results pri...
Source: New Harvard Health Information - July 13, 2015 Category: Consumer Health News Authors: Gregory Curfman, MD Tags: Heart Health heart attack heart disease NSAIDS Stroke Source Type: news

Risk of ischaemic stroke associated with non-steroidal antiinflammatory drugs and paracetamol: a population-based case-control study.
CONCLUSIONS: Diclofenac and aceclofenac increase the risk of ischaemic stroke while ibuprofen and naproxen do not. Dose, duration and baseline CV risk, but not aspirin use, appear to modulate the risk. Paracetamol does not increase the risk, even in patients at high background CV risk. This article is protected by copyright. All rights reserved. PMID: 25611553 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 22, 2015 Category: Hematology Authors: García-Poza P, de Abajo FJ, Gil MJ, Chacón A, Bryant V, García-Rodríguez LA Tags: J Thromb Haemost Source Type: research

Risk of ischaemic stroke associated with non‐steroidal antiinflammatory drugs and paracetamol: a population‐based case‐control study
ConclusionsDiclofenac and aceclofenac increase the risk of ischaemic stroke while ibuprofen and naproxen do not. Dose, duration and baseline CV risk, but not aspirin use, appear to modulate the risk. Paracetamol does not increase the risk, even in patients at high background CV risk.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - January 22, 2015 Category: Hematology Authors: Patricia García‐Poza, Francisco J. Abajo, Miguel J. Gil, Ana Chacón, Verónica Bryant, Luis A. García‐Rodríguez Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Risk of ischemic stroke associated with non‐steroidal anti‐inflammatory drugs and paracetamol: a population‐based case‐control study
ConclusionsDiclofenac and aceclofenac increase the risk of ischemic stroke while ibuprofen and naproxen do not. Dose, duration and baseline CV risk, but not aspirin use, appear to modulate the risk. Paracetamol does not increase the risk, even in patients with a high background CV risk.
Source: Journal of Thrombosis and Haemostasis - February 24, 2015 Category: Hematology Authors: P. García‐Poza, F. J. Abajo, M. J. Gil, A. Chacón, V. Bryant, L. A. García‐Rodríguez Tags: Original Article Source Type: research

Heart attack, stroke warning on pain relievers strengthened
Stephen FellerSILVER SPRING, Md., July 10 (UPI) -- The FDA is strengthening warnings on prescription and over-the-counter ibuprofen and naproxen pain relievers about increased risk for heart attack and stroke.
Source: Health News - UPI.com - July 10, 2015 Category: Consumer Health News Source Type: news

Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
CONCLUSION: On the basis of our meta-analysis, we can state that symptomatic benefits induced by the prolonged administration of celecoxib may be partially invalidated by a concomitant increase in vascular risk, particularly the increased risk of myocardial infarction found in celecoxib-treated patients, compared to controls taking placebo. In contrast, treatment with etoricoxib proved not to result in an increased risk of serious vascular events when compared with both the placebo and naproxen. Our meta-analysis also denotes that the alternative to COXIBs, represented by naproxen, does not show significant benefit in term...
Source: Minerva Cardioangiologica - November 18, 2015 Category: Cardiology Tags: Minerva Cardioangiol Source Type: research

Use of Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Relation to Cardiovascular Events: A Systematic Pharmacoepidemiological Review.
CONCLUSION: Further research is needed in order to devise new guidelines for safer use of NSAIDs. PMID: 27468710 [PubMed - as supplied by publisher]
Source: Current Vascular Pharmacology - July 26, 2016 Category: Drugs & Pharmacology Authors: Kontogiorgis C, Valikeserlis I, Hadjipavlou-Litina D, Nena E, Constantinidis TC Tags: Curr Vasc Pharmacol Source Type: research

High-dose painkiller heart risk: small but significant
Conclusion This large review adds to, and expands on, the current evidence on the risks of vascular disease and gastrointestinal complications for different NSAIDs. It largely concentrates on trials of high doses of NSAIDs that can only be prescribed by a doctor. It is unclear from this study whether there is any risk from taking lower doses available over the counter. While most experts advise that low-dose NSAIDs, taken occasionally, are safe for most people, an accompanying editorial points out that there are still “large gaps” in evidence on the risks with lower doses of NSAIDs. While the risk to individuals is sma...
Source: NHS News Feed - May 30, 2013 Category: Consumer Health News Tags: Medication Heart/lungs Source Type: news

Non ‐steroidal anti‐inflammatory drug‐induced cardiovascular adverse events: a meta‐analysis
Summary What is known and objectiveAlthough non‐steroidal anti‐inflammatory drugs (NSAIDs) have been studied in randomized, controlled trials and meta‐analyses in an effort to determine their cardiovascular (CV) risks, no consensus has been reached. These studies continue to raise questions, including whether cyclooxygenase‐2 (COX‐2) selectivity plays a role in conferring CV risk. We performed a meta‐analysis of current literature to determine whether COX‐2 selectivity leads to an increased CV risk. MethodsWe utilized randomized, controlled trials and prospective cohort studies. We selected eight NSAIDs based...
Source: Journal of Clinical Pharmacy and Therapeutics - November 30, 2016 Category: Drugs & Pharmacology Authors: B. R. Gunter, K. A. Butler, R. L. Wallace, S. M. Smith, S. Harirforoosh Tags: Review Article Source Type: research

Comparative evaluation of cardiovascular outcomes in patients with osteoarthritis and rheumatoid arthritis on recommended doses of nonsteroidal anti-inflammatory drugs
Conclusion: From the analysis conducted, it appears that the risk for cardiovascular events in arthritis patients on licensed doses of NSAIDs varies considerably and is likely to depend on the individual compound.
Source: Therapeutic Advances in Musculoskeletal Disease - August 4, 2014 Category: Orthopaedics Authors: Fabule, J., Adebajo, A. Tags: Original Research Source Type: research

Better than Aspirin for Your Heart
If you’ve been diagnosed with heart disease, the chances are you’ve been told to take low-dose aspirin every day as a preventative measure against heart attack and stroke. It’s most commonly prescribed for patients with congestive heart failure. This is the inability of your heart to pump as much blood as your body needs. And this is a big worry to me, because there is very little evidence that aspirin helps. In fact, regular use of aspirin — even baby aspirin — can do you more harm than good. Common Aspirin Beliefs The idea is that aspirin thins the blood, making it easier to pump.  It is also s...
Source: Al Sears, MD Natural Remedies - April 1, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Heart Health Source Type: news

Use of Non-Steroidal Anti-Inflammatory Drugs That Elevate Cardiovascular Risk: An Examination of Sales and Essential Medicines Lists in Low-, Middle-, and High-Income Countries
Conclusions Listing of NSAIDs on national EMLs should take account of cardiovascular risk, with preference given to low risk drugs. Diclofenac has a risk very similar to rofecoxib, which was withdrawn from worldwide markets owing to cardiovascular toxicity. Diclofenac should be removed from EMLs. Please see later in the article for the Editors' Summary
Source: PLoS Medicine - February 12, 2013 Category: Internal Medicine Authors: Patricia McGettigan et al. Source Type: research

NSAIDs and cardiovascular risk: An examination of sales and Essential Medicines Lists in low-, middle-, and high-income countries
Source: PLoS Medicine Area: News It is known that certain non-steroidal anti-inflammatory drugs (NSAIDs) increase the risk of myocardial infarction and stroke and should be avoided in patients at high risk of cardiovascular events. A study, published in PLoS medicine, investigated the extent to which evidence on cardiovascular risk with NSAIDs has translated into guidance and sales in 15 countries.   The authors identified that three drugs (rofecoxib, diclofenac, and etoricoxib) ranked consistently highest in terms of cardiovascular risk compared with nonuse and naproxen was associated with a low risk. Diclofenac...
Source: NeLM - Cardiovascular Medicine - February 15, 2013 Category: Cardiology Source Type: news

Taking over the counter pain relievers safely
For aching joints or a throbbing head, millions of Americans turn to aspirin, ibuprofen (Advil, Motrin), or other nonsteroidal anti-inflammatory drugs (NSAIDs) every day. They are generally safe, but if not used carefully NSAIDs can have a dark side, according to the September 2013 Harvard Women's Health Watch. NSAIDs are widely used because they perform double duty. “They not only relieve pain, but they reduce inflammation too,” says Dr. Lucy Chen, an assistant professor at Harvard Medical School and attending physician in the anesthesia, critical care, and pain medicine department at Massachusetts General Hos...
Source: New Harvard Health Information - August 23, 2013 Category: Consumer Health News Source Type: news

Managing migraine and other headache syndromes in those over 50
Abstract: Migraine in an older person may appear with sensory or motor phenomena (“late-life migraine accompaniments”), so that it may be confused with transient ischemic attack or stroke. An older patient may have cervicogenic headache in addition to migraine. Medication overuse headache is just as much of a problem in older patients as it is in younger ones. Abdominal migraine without headache can be seen in older adults as a migraine equivalent, just as it can occur in children. The most effective drugs for migraine prophylaxis in young people (divalproex, topiramate, metoprolol and propranolol) are similarly effect...
Source: Maturitas - May 1, 2013 Category: Primary Care Authors: Brett Dees, Rhonda Coleman-Jackson, Linda A. Hershey Tags: Reviews Source Type: research